Predictors of medication adherence in patients with type 2 diabetes mellitus

Current Medical Research and Opinion

Volumn 29, Issue 10, 2013, Pages 1275-1286

  Curkendall, Suellen M ^a   Thomas, Nina ^b   Bell, Kelly F ^b   Juneau, Paul L ^a   Weiss, Audrey J ^a  

^a IBM WATSON HEALTH   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Diabetes mellitus; Dipeptidyl peptidase 4 (DPP 4) inhibitor sulfonylurea compounds; Glucagon like peptide 1; Medication adherence; Saxagliptin; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SULFONYLUREA; TOLAZAMIDE;

ADULT; ARTICLE; COHORT ANALYSIS; DATA BASE; DEMOGRAPHY; DRUG SCREENING; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYPHARMACY; PRESCRIPTION; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADAMANTANE; ADULT; AGED; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PATIENT COMPLIANCE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84884494635     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.821056     Document Type: Article

References (45)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. Available at: http://www.cdc.gov/diabetes/pubs/factsheet11.htm [Last accessed 22 October 2012]
2. Centers for Disease Control and Prevention. Diabetes Report Card 2012. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2012. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ DiabetesReportCard.pdf [Last accessed 30 October 2012]
3. Boswell KA, Cook CL, Burch SP, et al. Associating medication adherence with improved outcomes: a systematic literature review. Am J Pharm Benefits 2012;4:e97-108
4. Jha AK, Aubert RE, Yao J, et al. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Diabetes Care 2012;31:1836-46
5. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74-109
6. Stuart BC, Simoni-Wastila L, Zhao L, et al. Increased persistency in medication use by U.S. Medicare beneficiaries with diabetes is associated with lower hospitalization rates and cost savings. Diabetes Care 2009;32:647-9
7. Ho PM, Rumself JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-41 (Pubitemid 44455165)
8. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958-71 (Pubitemid 37510603)
9. Cramer J. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24 (Pubitemid 38579798)
10. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118:27-34S
11. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011;65:314-22
12. DiMatteo MR. Variations in patients' adherence to medical recommendations. Med Care 2004;42:200-9
13. Duru OK, Schmittdiel JA, Dyer WT, et al. Mail-order pharmacy use and adherence to diabetes-related medications. Am J Manag Care 2010;16:33-40
14. Zhang L, Zakharyan A, Stockl KM. Mail-order pharmacy use and medication adherence among Medicare Part D beneficiaries with diabetes. J Med Econ 2011;14:562-7
15. Eaddy MT, Cook CL, O'Day K, et al. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T 2012;37:45-55
16. Farley JF, Wansink D, Lindquist JH, et al. Medication adherence changes following value-based insurance design. Am J Manag Care 2012;18:265-74
17. Gibson, TB, Song, X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 2010;16:589-600
18. Pollack M, Chastek B, Williams SA, et al. Impact of treatment complexity on adherence and glycemic control: an analysis of oral antidiabetic agents. J Clin Outcomes Manage 2010;17:257-65
19. Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence. Available at: http://www.pqaalliance.org/files/ PDCvsMPRfinal.pdf [Last accessed 14 October 2012]
20. Centers for Medicare and Medicaid Services. Medicare Health & Drug Plan Quality and Performance Ratings 2012, Part C & Part D Technical Notes. Available at: http://www.calquality.org [Last accessed 14 October 2012]
21. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009;31:2608-17
22. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
23. Jin J, Sklar GE, Oh VMS, et al. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag 2008;4:269-86 (Pubitemid 351460951)
24. Yang Y, Thumula V, Pace PF, et al. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther 2009;31:2178-88
25. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 2005;27:1064-73 (Pubitemid 41262464)
26. Bonafede MM, Kalsekar A, Pawaskar M, et al. Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis. BMC Endocr Dis 2001;11:3. Available at: http://www.biomedcentral.com/1472-6823/11/3 [Last accessed 4 December 2012]
27. Nau DP, Aikens JE, Pacholski AM. Effects of gender and depression on oral medication adherence in persons with type 2 diabetes mellitus. Gend Med 2007;4:205-13 (Pubitemid 350082736)
28. Miller MA. Gender-based differences in the toxicity of pharmaceuticals-The Food and Drug Administration's perspective. Int J Toxicol 2001;20:149-52 (Pubitemid 32646165)
29. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001;2:349-51 (Pubitemid 34017040)
30. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hypergly-cemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203
31. Hauber AB, Mohamed AF, Johnson FR. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med 2009;26:416-24
32. Polonsky WH, Anderson BJ, Lohrer PA, et al. Insulin omission in women with IDDM. Diabetes Care 1994;17:1178-85 (Pubitemid 24307454)
33. Tiv M, Viel J, Mauny F, et al. Medicare adherence in type 2 diabetes: The ENTRED Study 2007, a French population-based study. PLOS One 2012;7:e32412. Available at: http://www.plosone.org/article/fetchObject.action?uri= info%3Adoi%2F10.1371%2Fjournal.pone.0032412 &representation=PDF
34. Egede LE, Gebregziabher M, Hunt KJ, et al. Regional, geographic, and ethnic differences in medication adherence among adults with type 2 diabetes. Ann Pharmacother 2011;45:169-78
35. CVS Caremark. State of the States: Adherence Report (2012). Available at: http://www.cvscaremarkfyi.com/sites/all/themes/cvs-theme/11-CVS-346-state-of- adherence%20Brochure-FNL-web.pdf [Last accessed 19 October 2012]
36. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care 2007;45:521-8
37. Emslie-Smith A, Dowall J, Morris A. The problem of polypharmacy in type 2 diabetes. Br J Diabetes Vasc Dis 2003;3:54-6 (Pubitemid 37045610)
38. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001;23:1311-20 (Pubitemid 32804123)
39. Grant RW, Devita NG, Singer DE, et al. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003;26: 1408-12 (Pubitemid 36929171)
40. Dezil CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002;95:68-71 (Pubitemid 34131538)
41. Devine S, Vlahiotis A, Sundar H. A comparison of diabetes medication adherence and healthcare costs in patients using mail order pharmacy and retail pharmacy. J Med Econ 2010;13:203-11
42. Chang A, Liberman JN, Coulen C, et al. Value-based insurance design and antidiabetic medication adherence. Am J Pharm Benefits 2010;2: 39-44
43. Göke B, Gallwitz B, Eriksson J, et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010;64:1619-31
44. DiBonaventura MD, Wagner J, Girman CJ, et al. Multinational Internet-based survey of patient preference for newer oral or injectable type 2 diabetes medication. Patient Prefer Adherence 2010;4:397-406
45. Karve S, Cleves MA, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008;46:1125-33